ANALISIS EFEKTIVITAS BIAYA (CEA) PENGOBATAN KOMBINASI DAN OAT PADA PASIEN TUBERKULOSIS PARU DI RUMAH SAKIT UMUM IMELDA PEKERJA INDONESIA MEDAN

  • Alex Sinaga Universitas Imelda Medan
  • Astini Berutu Universitas Imelda Medan
Keywords: Cost Effectiveness Analysis, Citicoline Inj, Piracetam Inj, Stroke

Abstract

Tuberculosis (TB) is an infectious infectious disease caused by the bacterium Mycobacterium tuberculosis that can attack various organs, especially the lungs. Treatments that can be done in patients with pulmonary TB are treatments such as OAT (anti-tuberculosis drugs) which can be divided into single OAT and anti-tuberculosis drugs. combination drugs (drugs containing two or more active ingredients combined in one dosage form while maintaining the appropriate dose). This study aims to find out which treatment is more effective and cost-effective for pulmonary TB patients at Imelda Indonesian Workers Hospital in Medan. This research is a cohort study with snowball sampling technique. The conclusion of this study is that the ACER value of combination therapy is 75,490, and the ACER value of OAT is 92.130. The ICER value from the comparison of combination therapy and OAT was -5.762.

References

Adibhatla, R. M., Hatcher, J. F., 2005, Cytidine 5- Diphosphocholine (CDP-choline) in Stroke and other CNS disorder, Journal Neurochemistry Res., 70: 133-139.

Baroroh, F, Fauzi LA. Analisis biaya terapi stroke pada pasien rawat inap di rumah sakit PKU muhammadiyah bantul yogyakarta. J ilmu ibnu sina. 2017;2(1):93-101.

Davalos A., J. Castillo, Jose A. S., Julio J. S., Joan M., Sonia L., dkk. 2002, Oral Citicoline in Acute IschemicStroke: An Individual Patient Data Pooling Analysis Of Clinical Trials, Journal of American Heart Assosiation, 33:2850–2857.

Grosse D.S.,Teutsch M.S. Developing, Implementing and Population Intervention. Genetics and Prevention Effectiveness. Genetics and Public Health in 21st Century: Oxford University Press 2000.

Hauer A.J., Ynte M.R., Ale A., Ewoud J.van D., Peter J.K., Gert-Jan L., Paul J.N., Robert J.van O., Marieke C.V., Marieke J.W., L. Jaap K. and Catharina J.M., 2017, Age-Specific Vascular Risk Factor Profiles According to Stroke Subtype, Journal of the American Heart Association.

Junaidi, Iskandar (2004). Panduan Parktis Pencegahan Dan Pengobatan Stroke. Jakarta: Pt Bhuana Ilmu Popular.

Kementrian Kesehatan Republik Indonesia Riset Kesehatan Dasar (Riskesdas,2018). Https://Kesmas.Kemkes.Go.Id/Assets/Upload/Dir_519d41d8cd98f00/Files/Hasil-Riskesdas-2018_1274.Pdf. Diakses: 11 Februari 2018.

Lisabeth L, Bushel C. (2012). Stroke Risk in Women: The Role of Menopouse and Hormone Therapy. Lancet Neurology, 11, 82-91. http://doi.org/10.1016/S1474-4422(11)70269-1.

Praja. S. D. Hasmono. D. Syifa. N. (2013) Studi Penggunaan Obat Neuroprotektan Pada Pasien Stroke Iskemik. Pharmacy; ISSN: 1693-3591. 10(2): 147-149.

Refasi., L.N. Lolo., A.W. Bodhi.,W. (2018). Analisis Efektivitas Biaya (Cost Effectiveness Analysis) Pada Pengobatan Pasien Malaria Falciparum Di Rsud Nabire, Pharmacon; Issn: 2302- 2493.7(2):1-9.

Silalahi. B. (2017) Gambaran Faktor-Faktor Yang Mempengaruhi Terjadinya Stroke Pada Dewasa Dini Di Rumah Sakit X Kota Mesan. Jurnal Ilmiah Keperawatan Imelda: 331-334
Tri Murti, A. 2013. Farmakoekonomi Prinsip dan Metodologi. Bursa Ilmu, Jogyakarta.

Watila MM, Nyandaiti YW, Bwala SA, Ibrahim A. (2010). Gender Variation Risk Factors and Clinical Presentation of Acute Stroke, Northeastern Nigeria. Journal of Neuroscienceanda Behavioural Health, 3(3), 38-43.
Published
2022-09-30